| Identification | Back Directory | [Name]
1-[[(2-NITROPHENYL)AMINO]CARBONYL]-L-PROLYL-N-METHYL-3-(2-NAPHTHALENYL)-N-(PHENYLMETHYL)-L-ALANINAMIDE | [CAS]
180046-99-5 | [Synonyms]
SDZ NKT 343
1-[[(2-NITROPHENYL)AMINO]CARBONYL]-L-PROLYL-N-METHYL-3-(2-NAPHTHALENYL)-N-(PHENYLMETHYL)-L-ALANINAMIDE
L-Alaninamide, 1-[[(2-nitrophenyl)amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)- | [Molecular Formula]
C33H33N5O5 | [MDL Number]
MFCD00949605 | [MOL File]
180046-99-5.mol | [Molecular Weight]
579.65 |
| Chemical Properties | Back Directory | [Boiling point ]
892.8±65.0 °C(Predicted) | [density ]
1.327±0.06 g/cm3(Predicted) | [storage temp. ]
Store at +4°C | [solubility ]
Soluble to 100 mM in DMSO and to 100 mM in ethanol | [form ]
Powder | [pka]
11.66±0.70(Predicted) |
| Hazard Information | Back Directory | [Uses]
SDZ NKT 343 is a potent human NK1 tachykinin receptor antagonist. | [Biological Activity]
Highly selective human tachykinin NK 1 receptor antagonist (IC 50 values are 0.62 and 451 nM for human and rat receptors respectively) that displays > 130-fold selectivity over human NK 2 and NK 3 receptors. Potently antagonizes SP-induced Ca 2+ efflux in vitro and inhibits mechanical hyperalgesia in vivo . | [in vivo]
SDZ NKT 343 antagonized [Sar9]SP sulphone-evoked bronchoconstriction (70% reduction at 0.4 mg/kg, i.v.) in anaesthetized guinea-pigs[1]. | [IC 50]
hNK1: 0.62 nM (IC50); hNK2: 0.52 μM (Ki); hNK3: 3.4 μM (Ki) | [storage]
Store at -20°C |
|
|